HK Stock MarketDetailed Quotes

09995 REMEGEN

Watchlist
  • 27.300
  • +0.200+0.74%
Not Open Apr 18 16:08 CST
14.86BMarket Cap-8909P/E (TTM)

About REMEGEN Company

The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., led by Mr. Wang Weidong, and Dr. Fang Jianmin, a scientist studying in the US. Rongchang Biology is headquartered in Yantai City, Shandong Province, China, and has experimental research institutes and offices in China and the United States. Rongchang Biotech is committed to the discovery, development and commercialization of innovative, unique biopharmaceuticals, and has created a number of new biopharmaceuticals with significant clinical value for major diseases such as autoimmunity, oncology, and ophthalmology. Founded in 2008, the company is an innovative biopharmaceutical company with a global perspective. Since its establishment, it has focused on the fields of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bifacial antibodies. Company products: Tetasepp, verdicetuzumab, RC28, RC88, RC98, RC108, RC118, etc.

Company Profile

Symbol09995
Company NameREMEGEN
ISINCNE1000048G6
Listing DateNov 9, 2020
Issue Price52.10
Shares Offered76.54M share(s)
FoundedJul 4, 2008
Registered AddressChina
Chairmanweidong wang
Secretaryshaojingtanbairu tong
Audit InstitutionErnst & Young
Company CategoryMainland registration of Mainland Individuals control
Registered OfficeNo. 58, Beijing Middle Road, Yantai Development Zone, Yantai Area, Shandong Pilot Free Trade Zone, China
Head Office and Principal Place of Business40th Floor, Dah Sing Financial Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees3615
MarketHong Kong motherboard
Phone0535-3573685
Fax0535-6113517
Emailrcsw@remegen.cn
Websitehttp://www.remegen.cn/
BusinessFounded in 2008, the company is an innovative biopharmaceutical company with a global perspective. Since its establishment, it has focused on the fields of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bifacial antibodies.

Company Executives

  • Name
  • Position
  • Salary
  • weidong wang
  • Chairman，Executive Director，Chairman of the Nomination Committee，Strategy Committee Members
  • --
  • jianmin fang
  • CEOs，Chief Scientific Officer，Executive Director，Chairman of the Strategy Committee，Authorized Representative
  • --
  • ruyi he
  • Clinical Research Supervisor，Chief Medical Officer，Executive Director，Strategy Committee Members
  • --
  • jian lin
  • Executive Director，Remuneration Committee Members
  • --
  • liqiang wang
  • Non-executive directors，Audit Committee Members，Strategy Committee Members
  • --
  • xiaodi su
  • Non-executive directors，Strategy Committee Members
  • --
  • yunjin chen
  • Independent Non-Executive Director，Remuneration Committee Chairman，Audit Committee Members
  • --
  • xianjing hao
  • Independent Non-Executive Director，Chairman of the Audit Committee，Nomination Committee Members，Remuneration Committee Members
  • --
  • lan ma
  • Independent Non-Executive Director，Nomination Committee Members，Strategy Committee Members
  • --
  • guangke ren
  • auditors
  • --
  • yupeng li
  • auditors
  • --
  • zhuanglin li
  • auditors
  • --
  • daotian fu
  • President
  • --
  • qingkai wen
  • Board Secretary
  • --
  • shaojing tong
  • chief financial officer，Joint Company Secretary
  • --
  • bairu tan
  • Joint Company Secretary，Authorized Representative
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg